Posts in: heltzen

WTR Healthcare Happenings
heltzennutraceuticalspress clippingspodcastNCT
WTR podcast: Unlocking Hard-to-Scale Molecules with AI-Driven, Cell-Free BiomanufacturingMay 6, 2026
Podcast: CEO Heltzen @ Executive Insights for Life Sciences Innovators
heltzenpress clippingsvideopodcast
Podcast: CEO Heltzen @ Executive Insights for Life Sciences InnovatorsApril 20, 2026
Biotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael Heltzen
heltzenpress clippingsvideopodcast
Biotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael HeltzenApril 13, 2026
Nasdaq's 'Amplify Spotlight'
heltzeninvestorpress clippingsvideo
Nasdaq: Michael B. Spector interviews CEO HeltzenFebruary 5, 2026
CEO Heltzen interviewed by Maxine Hoover at the Beryl Elites’ Investment Conference in New York City
heltzeninvestorpress clippingsvideo
Beryl Elites: What is Artificial Evolution - an interview with CEO HeltzenJanuary 7, 2026
CEO Michael Heltzen at the Beryl Elite's 'AI in Life Sciences' panel
heltzeninvestorpress clippings
Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel)December 15, 2025
100× scale-up of NCT production achieved
heltzenpress releaseinvestornutraceuticalsmedicineNCTkorman
eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversionDecember 11, 2025
'The Upside' interview: Michael Heltzen & Lou Basenese
heltzeninvestornutraceuticalsmedicinepress clippingsvideoNCTcannabinoids
'The Upside' interview: Michael Heltzen & Lou BaseneseNovember 18, 2025
CEO, Michael Heltzen is interviewed by Jane King
heltzeninvestorpress clippingsvideo
Jane King interviews CEO, Michael Heltzen, in New YorkNovember 12, 2025
CEO of eXoZymes on ‘AI in Life Sciences’ panel at the Beryl Elites’ Investment Conference
heltzeninvestor
CEO of eXoZymes on ‘AI in Life Sciences’ panel at the Beryl Elites’ Investment ConferenceOctober 30, 2025
Previous page
Page 1 of 3
Next page